Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Fady Ibraham Malik sold 2,000 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $45.98, for a total transaction of $91,960.00. Following the sale, the executive vice president now owns 116,071 shares of the company's stock, valued at approximately $5,336,944.58. The trade was a 1.69 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Fady Ibraham Malik also recently made the following trade(s):
- On Tuesday, February 4th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $48.06, for a total transaction of $96,120.00.
- On Tuesday, January 21st, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $45.92, for a total transaction of $91,840.00.
- On Tuesday, January 7th, Fady Ibraham Malik sold 2,000 shares of Cytokinetics stock. The shares were sold at an average price of $49.32, for a total transaction of $98,640.00.
- On Tuesday, December 10th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $50.64, for a total transaction of $369,672.00.
- On Tuesday, November 26th, Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock. The shares were sold at an average price of $50.16, for a total transaction of $366,168.00.
Cytokinetics Stock Down 1.7 %
Shares of NASDAQ:CYTK opened at $45.39 on Wednesday. The company has a market capitalization of $5.36 billion, a PE ratio of -8.44 and a beta of 0.83. The company has a current ratio of 9.28, a quick ratio of 9.28 and a debt-to-equity ratio of 5.93. Cytokinetics, Incorporated has a twelve month low of $40.53 and a twelve month high of $81.36. The firm has a 50 day simple moving average of $47.33 and a 200-day simple moving average of $51.59.
Analyst Ratings Changes
A number of equities research analysts have weighed in on the stock. JMP Securities reiterated a "market outperform" rating and set a $78.00 price target on shares of Cytokinetics in a research report on Friday, February 7th. Evercore ISI raised shares of Cytokinetics to a "strong-buy" rating in a research note on Friday, February 7th. Morgan Stanley raised shares of Cytokinetics from an "equal weight" rating to an "overweight" rating and lowered their price objective for the company from $70.00 to $67.00 in a research note on Thursday, February 13th. HC Wainwright reissued a "buy" rating and issued a $120.00 price objective on shares of Cytokinetics in a research note on Tuesday, January 21st. Finally, Stifel Nicolaus began coverage on shares of Cytokinetics in a research note on Wednesday, January 22nd. They issued a "buy" rating and a $80.00 price objective for the company. Two research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $82.00.
Read Our Latest Stock Report on CYTK
Institutional Trading of Cytokinetics
Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its position in shares of Cytokinetics by 1.3% during the 4th quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company's stock worth $560,520,000 after buying an additional 154,216 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its position in shares of Cytokinetics by 11.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company's stock worth $505,780,000 after buying an additional 1,062,136 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Cytokinetics by 4.0% during the 3rd quarter. Geode Capital Management LLC now owns 2,848,584 shares of the biopharmaceutical company's stock worth $150,433,000 after buying an additional 109,938 shares during the last quarter. Deep Track Capital LP lifted its position in shares of Cytokinetics by 296.9% during the 4th quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company's stock worth $117,600,000 after buying an additional 1,870,094 shares during the last quarter. Finally, Vestal Point Capital LP lifted its position in shares of Cytokinetics by 56.7% during the 4th quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company's stock worth $110,544,000 after buying an additional 850,000 shares during the last quarter.
Cytokinetics Company Profile
(
Get Free Report)
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
